Literature DB >> 19125952

Plasma exchange in combination with online-hemodiafiltration as a promising method for purifying the blood of fulminant hepatitis patients.

Kazuaki Inoue1, Akishi Kourin, Tsunamasa Watanabe, Masaya Yamada, Hiroshi Yasuda, Makoto Yoshiba.   

Abstract

BACKGROUND: Fulminant hepatitis is an intractable disease caused by various etiological agents. Artificial liver support (ALS) is a symptomatic treatment used to control serious symptoms, such as bleeding tendency, hepatic coma, and brain edema.
METHODS: The present study involved four patients with fulminant hepatitis who were admitted to Showa University Fujigaoka Hospital between January 2007 and June 2007. All four patients were subacute type disease of indeterminate etiology. The four patients were placed on an ALS system that comprised plasma exchange and online hemodiafiltration. The effect of the ALS on various symptoms of fulminant hepatitis was evaluated, and the levels of glutamine in the patients' plasma samples and the discarded buffer were assayed using automatic analyser.
RESULTS: Three of the four patients regained full consciousness and survived. The remaining patient died despite recovering from hepatic coma with ALS. The plasma glutamine levels were significantly reduced by artificial liver support. The estimated distribution volume of removed Gln ranged from 30 L to 60 L.
CONCLUSIONS: Plasma exchange in combination with online hemodiafiltration is a promising and effective method for purifying the blood of patients with fulminant hepatitis.

Entities:  

Year:  2008        PMID: 19125952     DOI: 10.1111/j.1872-034X.2008.00426.x

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  1 in total

1.  Algorithm to determine the outcome of patients with acute liver failure: a data-mining analysis using decision trees.

Authors:  Nobuaki Nakayama; Makoto Oketani; Yoshihiro Kawamura; Mie Inao; Sumiko Nagoshi; Kenji Fujiwara; Hirohito Tsubouchi; Satoshi Mochida
Journal:  J Gastroenterol       Date:  2012-03-09       Impact factor: 7.527

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.